Literature DB >> 9092116

Invasive therapy of metastatic colorectal cancer to the liver.

K W Millikan1, E D Staren, A Doolas.   

Abstract

Resection, when possible, is still the best hope for cure of colorectal metastasis to the liver. Poor prognostic indicators for survival include heavy tumor burden, the presence of extrahepatic disease, synchronous metastasis, and the inability to perform resection with a 1-cm margin. Questionable poor prognostic indicators include multiple metastases (more than three), bilobar disease, and the need to transfuse patients during resection. Preoperatively, a patient must be evaluated for the extent of liver disease and the presence of extrahepatic disease with a CT of the abdomen and routine studies of the chest. Intraoperatively, a surgeon should be able to perform or obtain ultrasonography of the liver to detect occult metastases and delineate anatomy. The surgeon should be experienced in wedge, segmental, and lobar resection. Equipment for cryotherapy and arterial infusion devices should be available, and staff experienced in these modalities should be present. If all of these factors are present, the options for the invasive treatment of colorectal metastasis to the liver can be carried out in a manner that should provide the most benefit at a low morbidity to this population of patients.

Entities:  

Mesh:

Year:  1997        PMID: 9092116     DOI: 10.1016/s0039-6109(05)70531-4

Source DB:  PubMed          Journal:  Surg Clin North Am        ISSN: 0039-6109            Impact factor:   2.741


  26 in total

1.  Overall survival or other clinical benefits from adjuvant selective intraarterial chemotherapy in patients undergoing curative liver resection for metastatic colorectal tumor.

Authors:  P A Clavien; M Selzner; M A Morse
Journal:  Ann Surg       Date:  1999-10       Impact factor: 12.969

2.  Laparoscopic hepatic resection for metastatic liver tumor of colorectal cancer: comparative analysis of short- and long-term results.

Authors:  Shuichi Iwahashi; Mitsuo Shimada; Tohru Utsunomiya; Satoru Imura; Yuji Morine; Tetsuya Ikemoto; Yusuke Arakawa; Hiroki Mori; Mami Kanamoto; Shinichiro Yamada
Journal:  Surg Endosc       Date:  2013-08-31       Impact factor: 4.584

3.  Silibinin suppresses growth and induces apoptotic death of human colorectal carcinoma LoVo cells in culture and tumor xenograft.

Authors:  Manjinder Kaur; Balaiya Velmurugan; Alpna Tyagi; Gagan Deep; Suchitra Katiyar; Chapla Agarwal; Rajesh Agarwal
Journal:  Mol Cancer Ther       Date:  2009-07-28       Impact factor: 6.261

Review 4.  The role of vitamin D in hepatic metastases from colorectal cancer.

Authors:  E Shaw; N Massaro; N T Brockton
Journal:  Clin Transl Oncol       Date:  2017-08-11       Impact factor: 3.405

Review 5.  Simultaneous laparoscopic resection of primary colorectal cancer and associated liver metastases: a systematic review.

Authors:  R M Lupinacci; W Andraus; L B De Paiva Haddad; L A Carneiro D' Albuquerque; P Herman
Journal:  Tech Coloproctol       Date:  2013-09-21       Impact factor: 3.781

Review 6.  Is there a genetic signature for liver metastasis in colorectal cancer?

Authors:  Cristina Nadal; Joan Maurel; Pere Gascon
Journal:  World J Gastroenterol       Date:  2007-11-28       Impact factor: 5.742

7.  Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver?

Authors:  Markus Selzner; Thomas F Hany; Peer Wildbrett; Lucas McCormack; Zakiyah Kadry; Pierre-Alain Clavien
Journal:  Ann Surg       Date:  2004-12       Impact factor: 12.969

8.  Overexpression of FMNL2 is closely related to metastasis of colorectal cancer.

Authors:  Xi-Ling Zhu; Li Liang; Yan-Qing Ding
Journal:  Int J Colorectal Dis       Date:  2008-07-30       Impact factor: 2.571

9.  Additional value of FDG-PET/CT in management of "solitary" liver metastases: preliminary results of a prospective multicenter study.

Authors:  Gaia Grassetto; Adriano Fornasiero; Giorgio Bonciarelli; Elena Banti; Lucia Rampin; Maria Cristina Marzola; Arianna Massaro; Fabrizio Galeotti; Giuseppe Del Favero; Felice Pasini; Anna Maria Minicozzi; Adil Al-Nahhas; Claudio Cordiano; Domenico Rubello
Journal:  Mol Imaging Biol       Date:  2009-07-22       Impact factor: 3.488

10.  A cost-utility analysis of treatments for malignant liver tumours: a pilot project.

Authors:  Andrew McKay; Trish Kutnikoff; Mark Taylor
Journal:  HPB (Oxford)       Date:  2007       Impact factor: 3.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.